Adaptimmune Therapeutics Receives Orphan Drug Designation

- September 9th, 2019

Adaptimmune Therapeutics (NASDAQ:ADAP) has announced that the US Food and Drug Administration (FDA) has granted it orphan drug designation for its SPEAR T-cells targeting MAGE-A4 to treat soft tissue sarcomas. As quoted in the press release:  Orphan Designation by FDA was created to encourage the development of drugs for rare diseases, such as sarcomas. “We … Continued

Adaptimmune Therapeutics (NASDAQ:ADAP) has announced that the US Food and Drug Administration (FDA) has granted it orphan drug designation for its SPEAR T-cells targeting MAGE-A4 to treat soft tissue sarcomas.

As quoted in the press release:

 Orphan Designation by FDA was created to encourage the development of drugs for rare diseases, such as sarcomas.

“We recently started SPEARHEAD-1 treating patients with synovial sarcoma and myxoid/round cell liposarcoma (MRCLS), with the aim to launch ADP-A2M4 in 2022,” said Elliot Norry, Adaptimmune’s interim Chief Medical Officer. “This orphan drug status is another key milestone in achieving our goal of providing this much-needed therapy to people living with these rare and deadly cancers, for which there are few other treatment options.”

Click here to read the full press release.

Is the biotech market the perfect mesh between the technology and pharmaceutical market?

 
Read our FREE outlook report below!
 

 

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select All
Select None

Leave a Reply

Your email address will not be published. Required fields are marked *